Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 4/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.32 |
| ▸ | ATR | Q13535 | 2/20 | 0.32 |
| ▸ | ATRIP | Q8WXE1 | 2/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040302 | 0.93 | BRD4 (0.32) | DRD4BRD4CREBBPATRATRIP | |
| SCHEMBL3046394 | 0.89 | NR1H2 (0.33) | BRD4CREBBPTBK1ATRATRIP | |
| SCHEMBL3037182 | 0.89 | ACHE (0.37) | TBK1NR1H2ACHE | |
| SCHEMBL3046302 | 0.89 | NR1H2 (0.38) | BRD4CREBBPTBK1ATRATRIP | |
| SCHEMBL3040303 | 0.87 | ESR1 (0.34) | DRD4MCHR1TBK1HDAC1HDAC6 | |
| SCHEMBL3034089 | 0.87 | NR1H2 (0.35) | BRD4CREBBPTBK1ATRATRIP | |
| SCHEMBL5046925 | 0.87 | TBK1 (0.35) | TBK1ATRATRIPNR1H2 | |
| SCHEMBL3044037 | 0.87 | ABCB1 (0.36) | — | |
| SCHEMBL3840174 | 0.87 | NR1H2 (0.37) | BRD4CREBBPTBK1ATRATRIP | |
| SCHEMBL3051382 | 0.87 | NR1H2 (0.36) | BRD4CREBBPTBK1ATRATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1880993-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | NR4A1, NR5A2, PRMT8 | DRD4 88/4885MCHR1 244/4885BRD4 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.